U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/701,870

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number 10/701,870

Filing Date 11/05/2003

First Named Inventor Fritz Sieber

Art Unit 1645

Examiner Name N/A

Attorney Docket Number 650053,91649

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	IVO.	Number-Kind Code ^{2 (F known)}	MINI-DD-1111		
MT.	1	^{US-} 6,033,917	03-07-2000	Spallholz, et al.	
		US-			
		US-			
		US-			····
		us-			···
		US-			
		US-			
		US-	-		
		US-			
		US-		-	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
<u> </u>		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ,	
						<u> </u>	
	L					L	
						<u> </u>	

Examiner Signature	A Trans	Date Considered	03.11.05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this formwhith next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usptc.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, it kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				e required to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
Substitute to the 1975 FTS				Application Number	10/701,870	
INF	ORMATI	ON DIS	CLOSURE	Filing Date	11/05/2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Fritz Sieber	
				Art Unit	1645	
(Use as many sheets as necessary)			ecessary)	Examiner Name	N/A	
Sheet	2	of	3	Attorney Docket Number	650053.91649	

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.				
		Günther WHH, Searle R. and Sieber F; Structure-Activity Relationships in the Antiviral and Antileukemic Photoproperties of Merocyanine Dyes; Seminars in Hematology, Vol. 29, No. 2, pp. 88-94, 1992.	-			
1	3	Günther WHH, Searle R and Sieber F; Photosensitizing Merocyanine Dyes Based on Selenobarbituric Acid; Phosphorus, Sulfur, and Silicon, Vol. 67: pp. 417-424, 1992.				
	4	Krieg M, Bilitz JM, Traul DL and Sieber F; Photosensitizing Oxonol Dyes with Antineoplastic Activity, Cancer Research, Therapy and Control, Vol. 4, pp. 163-172, 1995.				
	5	Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH: Pre-Clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts In Vivo; Int. J. Cancer: 92, 718-724, 2001.				
6		Wunder A, Müller-Ladner U, Stelzer EHK, Funk J., Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C; Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis; The Journal of Immunology, 170, 4793-4801, 2003.				
	7	Yan L, Yee JA, Boylan LM, Spallholz JE; Effect of Selenium Compounds and Thiols on Human Mammary Tumor Cells, Biological Trace Element Research, Vol 30, pp. 145-162, 1991.				
	8	Zhang J-S, Gao X-Y, Zhang L-D, Bao Y-P; Biological effects of a nano red elemental selenium, BioFactors 16, 27-38, 2001.				
	9	Huang B, Zhang J, Hou J, Chen C; Free Radical Scavenging Efficiency of Nano-Se In Vitro; Free Radical Biology & Medicine, Vol. 35, No. 7, pp. 805-813, 2003.				
	10	Sieber F, Dazlano J-P, Anderson GS, Miyagi K, Sampson RW, Tsujino I, Günther WHH, Krieg M, Bousbaa J and Försterling FH; Collodial Selenium Generated by Photobleaching of Selenomerocyanine Dyes Combines with Serum Macromolecules to Form Conjugates that are Preferentially Cytotoxic to Leukemia and Selected Solid Tumor Cells: Blood 100, 224b, 2002	,			
Miyagi K, Sampson RW, Tsujino I, Gunther WHH, Krieg M and Sieber F; Proteinated subnanoparticles of elemental selenium potentiate the anti-tumor effect of ionizing radiation and selected chemotherapeutic age: Proceedings of the American Association Cancer Research, Vol. 44, 385, 2003.						

Examiner Signature 7 T9	Date Considered	03.11.05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with new communication to applicant.

considered. Include copy of this form with right communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3 2004 Plea	ase fipe a pl	us sign (+) inside this b work Reduction Act of	DOX → + 1	Approv U. S. Patent and Tradem espond to a collection of informatic	PTO/SB/08B (08-00) yed for use through 10/31/2002. OMB 0651-0031 hark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
RAO	Substitu	ite for form 1449B/PTC)	Complete if Known		
I			·	Application Number	10/701/870	
ı	INF	ORMATION	I DISCLOSURE	Filing Date	11/05/2003	
- 1	STA	TEMENT E	BY APPLICANT	First Named Inventor	Fritz Sieber	
- 1	• • • • • • • • • • • • • • • • • • • •		2. 7 2.07	Group Art Unit	1645	
l		(use as many s	heets as necessary)	Examiner Name	N/A	
(Sheet	3	of 3	Attorney Docket Number	650053.91649	

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	L ₅		
AT.	12	Sieber F; Proteinated Subnanoparticles of Colloidal Selenium: A New Class of Anti-Leukemia/Lymphoma Agents; Leukemia 17: 683, 2003.			
A.T.	13	Oral Presentation at 32nd Annual Scientific Meeting of the International Society for Experimental Hematology, Paris (France), July 7, 203.			
·					
		·			
		·			
			_		

Examiner Signature	N. Ter	Date Cons	e sidered	03,11,05
	——————————————————————————————————————			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.